GenorBio Enlists MabSpace to Discover mAbs

Shanghai's Genor Biopharma will collaborate with MabSpace Biosciences, a Hong Kong-Suzhou antibody discovery company, which will develop novel antibodies against unnamed targets for Genor. MabSpace will be responsible for discovery while GenorBio will develop the candidates further and own global rights. MabSpace will receive upfront R&D funding plus regulatory milestones and royalties. It was the second contract for MabSpace this week: earlier the company announced a similar deal with Jiangsu Hengrui Medicine. More details.... Stock Symbol: (SHZ: 200513) Share this with colleagues: // //